NCT00715663

Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes

A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoMix® 30 FlexPen® as Monotherapy, or in Combination With OHA, in Treatment of Type 2 Diabetic Patients in Routine Clinical Practice: A Post-Marketing Surveillance Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,584 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study is conducted in Asia. The aim of this observational study is to evaluate safety, efficacy and convenience in using NovoMix® 30 FlexPen® in type 2 diabetes under normal clinical practice conditions.

Conditions

• Diabetes
• Diabetes Mellitus, Type 2
• Delivery Systems

Interventions

Type	Name	Description
DRUG	biphasic insulin aspart 30	No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation

Timeline

• Start date: 2007-02-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2008-07-15
• Last updated: 2016-12-13

Locations

1 site across 1 country: Indonesia